MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Ionis Pharmaceuticals Inc

Abierto

SectorSalud

29.58 0.54

Resumen

Variación precio

24h

Actual

Mínimo

28.69

Máximo

29.84

Métricas clave

By Trading Economics

Ingresos

36M

-104M

Ventas

93M

227M

P/B

Media del Sector

539.57

57.333

BPA

-0.43

Margen de beneficio

-46.055

Empleados

1,069

EBITDA

44M

-81M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+87.59% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-162M

4.5B

Apertura anterior

29.04

Cierre anterior

29.58

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Ionis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

12 sept 2024, 17:01 UTC

Principales Noticias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 sept 2024, 11:00 UTC

Principales Noticias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Comparación entre iguales

Cambio de precio

Ionis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

87.59% repunte

Estimación a 12 meses

Media 55.47 USD  87.59%

Máximo 78 USD

Mínimo 38 USD

De acuerdo con 20 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

20 ratings

12

Comprar

8

Mantener

0

Vender

Puntuación técnica

By Trading Central

29.04 / 30.12Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.